



- Partnership between *IJDP* and INHSU
- INHSU, an affiliated organisation of *IJDP*
- INHSU guest-edited special content in *IJDP*




**Journal overview:** [www.ijdp.org](http://www.ijdp.org)

- 29 years!
- Research on health, social and policy effects
- Impact Factor of **4.24**; Ranked 3<sup>rd</sup>
- 1100+ submitted papers a year (2017)
- 580,000+ article downloads a year (2017)
- 55% rejection rate (2017)
- Good proportion of free-to-access material
- 5 senior editors, Editorial Board of 60
- 2 affiliated societies: ISSDP, and **INHSU**




## Partnership with INHSU

- INHSU is now an affiliated society of *IJDP*
- Shared interest in evidencing drug user health
- Free annual subscriptions to all INSHU members
- Free annual subscriptions to all INHSU delegates
- Guest-edited special content
- INSHU representation on the editorial team




## Special content: Hepatitis C

- Previous special content, 2015 & 2017
- 2017: Grebely, Bruggman, Treloar & Dore
- Comprised 27 papers
- The most cited issue in 2017



# Call for papers: Hepatitis C

- Upcoming guest-edited special content, 2019
- *Striving Towards Elimination*
- Grebely, Bruneau, Treloar, Hazarizadeh, Lazarus
- Call for abstracts, **November 1<sup>st</sup> 2018**
- Deadline for submissions, **December 14<sup>th</sup> 2018**
- Original empirical research and reviews
- Especially keen for submissions focusing on lower income settings, and which represent consumer voices
- All material free to access for 30-60 days
- Publication to coincide with INHSU 2019
- Call for abstracts/papers at: **ijdp.org**



## SPECIAL ISSUE

### Striving towards the elimination of hepatitis C virus infection among people who inject drugs

GUEST EDITORS:  
**JASON GREBELY,**  
**JULIE BRUNEAU,**  
**CARLA TRELOR,**  
**BENZAD HAZARIZADEH,**  
**JEFFREY LAZARUS**

#### CALL FOR PAPERS

We invite the following three types of contribution:

- Research papers based on empirical research (4,000 words, maximum 6 Figures/Tables)
- Social research papers based on empirical research (5,000 words, maximum 3 Figures/Tables)
- Review papers - particularly systematic reviews (4,000 words, maximum 6 Figures/Tables)
- Policy analysis (4,000 words, maximum 4 Figures/Tables)

(For other formatting requirements, please see IJDP guidance for authors at:  
[http://www.elsevier.com/locate/journaldescription.cws\\_home/600949/authorinstructions](http://www.elsevier.com/locate/journaldescription.cws_home/600949/authorinstructions))

We are interested in papers that explore expanding access to care/treatment for HCV among people who inject drugs across the following themes:

- Prevention of HCV infection among people who inject drugs (including novel treatment as prevention (TasP) studies)
- Strategies to enhance HCV testing, linkage to care, and treatment among people who inject drugs
- HCV DAA treatment for people who inject drugs, including novel strategies and settings to improve HCV treatment outcomes
- Reinfection following successful treatment among people who inject drugs
- How political and economic contexts shape treatment access, especially in lower-income settings.

We are especially interested in receiving papers based on empirical research and/or analysis from all geographic regions including from lower- and middle-income countries. We also encourage the inclusion of consumer voice/s in this collection.

The deadline for submission of outline abstracts is **1st November 2018**. Interested authors can contact the Guest Editors directly at any time to discuss their proposed submission. Queries and outline abstracts (300 word maximum) should be e-mailed to Jason Grebely at [jgrebely@kirby.unsw.edu.au](mailto:jgrebely@kirby.unsw.edu.au). Full submissions are due on **14<sup>th</sup> December 2018**. The special issue will be published coinciding with the 8th International Symposium on Hepatitis C in Substance Users (September 2019).

AVAILABLE ONLINE AT [ijdp.org](http://ijdp.org)

